Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 15;11:5878. doi: 10.1038/s41598-021-85412-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Effects of L1 mimetic compounds on the regeneration of oligodendrocytes in the spinal cord after oligodendrocyte ablation. All images are lateral views of the spinal cord of Tg(mbpa:gal4-vp16;uas:gfp;uas:NTR-mCherry) larvae at 8 days post-fertilization (dpf), anterior to the left and dorsal to the top. Fluorescence indicates MBP-positive oligodendrocytes and myelin sheaths in the spinal cord (a–i). White asterisks indicate debris of vacuolated oligodendrocytes. (j) Quantification of the number of oligodendrocytes per 2-somite area. Control: 22.27 ± 3.15, MTZ: 10.8 ± 2.90, recovery: 13.33 ± 2.55, 100 nM tacrine: 15.4 ± 2.41, 250 nM tacrine: 17.6 ± 2.41, 500 nM tacrine: 15.5 ± 1.64, 5 μM duloxetine: 11.9 ± 2.84, 10 μM duloxetine: 17.6 ± 4.05, 20 μM duloxetine: 16.5 ± 3.06. (k) Quantification of the number of vacuolated cells per 2-somite area. Control: 0, MTZ: 10.4 ± 2.36, recovery: 7.67 ± 1.68, 100 nM tacrine: 5.7 ± 2.16, 250 nM tacrine: 4 ± 1.73, 500 nM tacrine: 4.1 ± 2.02, 5 μM duloxetine: 5.2 ± 1.99, 10 μM duloxetine: 3.6 ± 1.84, 20 μM duloxetine: 4.5 ± 1.58. n = 15 for the control, recovery, 250-nM tacrine, and 10-μM duloxetine groups; n = 18 for the MTZ group; n = 10 for the 100- and 500-nM tacrine and 1-, and 20-μM duloxetine groups. ***p < 0.001; **p < 0.01; *p < 0.05; n.s., not significant. Scale bar, 25 μm.